



15 December 2022

**Acrux and Amring Pharmaceuticals
mutually terminate co-development agreement**

Melbourne, Australia; Acrux Limited (ASX:ACR)

Acrux and Amring Pharmaceuticals Inc. have mutually agreed to terminate the agreement for the development and commercialisation of a generic topical product for the United States market. Acrux retains exclusive ownership of all rights and Intellectual Property associated with the Product.

The Product is at an advanced stage of development and our target is to submit the Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) in late 2023.

Acrux is seeking to appoint a commercial licensing partner to launch the product after receipt of the necessary approvals from FDA.

Authorised by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis
Acrux Limited
CEO & Managing Director
P: + 61 3 8379 0100
E: michael.kotsanis@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

For further information on Acrux, visit www.acrux.com.au